Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1990-01-26
1991-04-30
Dees, Jose G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546127, 546128, 546203, 560 58, 514456, 514534, A01N 4316, A61K 3135
Patent
active
050118536
ABSTRACT:
This invention discloses the use of muscarinic anti-cholinergic agents for reducing or preventing the toxic or lethal effects (such as seizures and brain damage) caused by cholinergic neurotoxins. The parent application disclosed that certain muscarinic anti-cholinergics classified as aryl-cycloalkyl-alkanolamines are effective in reducing or preventing the neurotoxicity of soman, a powerful nerve gas. This invention extends that discovery and identifies other muscarinic anti-cholinergic agents, including scopolamine, benactyzine, and benztropine, as highly effective and useful agents to protect against two major classes of cholinergic neurotoxins (acetylcholine receptor agonists, and cholinesterase inhibitors). Analogs of those compounds may also be effective in protecting against cholinergic neurotoxicity, as can be determined through routine screening tests using rats. It has been discovered that protection against seizures induced by lithium and pilocarpine (drugs that are widely available and used frequently in research) provides a good indicator of effectiveness against soman, a nerve gas which is heavily restricted and extremely dangerous.
REFERENCES:
patent: 4945097 (1990-07-01), Olney
Niemegeers et al., Archives Internationales de Pharmacodynamie et de Therapie, vol. 259, pp. 153-165, 1982.
Jovic et al., Chemical Abstract, vol. 73, p. 236, 1970, 118907m.
Lin et al., Chemical Abstract, vol. 110, p. 235, 1989, 187,417.
McLeod, C. G. et al., "Acute Neuropathology in Soman-Poisoned Rats", Neurotoxicology 5: 53-58 (1984).
Olney, J. W., "Excitatory Transmitters and Epilepsy-Related Brain Damage", Intl. Rev. Neurobiol. 27: 337-362 (1985).
Clifford, D. B. et al., "The Functional Anatomy and Pathology of Lithium-Pilocarpine and High-Dose Pilocarpine Seizures", Neurosci. 23: 953-968 (1987).
Olney, J. W. et al., "Anti-Parkinsonian Agents Are Phencyclidine Agonists and N-Methyl Aspartate Antagonists", Eur. J. Pharmacol. 142: 319-320 (1987).
Shih, T. M. et al., "Studies of Potential Anticonvulsants in Soman Poisoning", Soc. for Neurosci. Abstr. 15: 623 (1989).
Stitcher et al., "Effect of Pyridostigmine and Cholinolytics on Cholinesterase and Acetylcholine in Soman-Poisoned Rats", Drug and Chemical Toxicology 1(4): 355-362 (1978).
Pazdernik et al., "Effects of Antidotes on Soman-Induced Brain Changes", Arch. Toxicol., Suppl. 9: 333-336 (1986).
Dunn, M. A. and Sidell, F., "Progress in Medical Defense Against Nerve Agents", J. Amer. Med. Assn. 262(5): 649-652 (1989).
Stryer, L., Biochemistry, 2nd Edition, pp. 890-893 (Freeman and Company, San Francisco).
Carr Deborah D.
Dees Jos,e G.
Washington University
LandOfFree
Compounds for treatment of cholinergic neurotoxins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for treatment of cholinergic neurotoxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for treatment of cholinergic neurotoxins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-640636